课题基金 / 基金详情

Intermountain Program on Antibiotic Resistance and microbial Threats (IMPART)

Intermountain Program on Antibiotic Resistance and microbial Threats (IMPART)
抗生素耐药性和微生物威胁山间计划 (IMPART)
批准号:
10646169
负责人:
MICHAEL A. RUBIN
金额:
$73.72万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-06-01 至 2026-05-31

项目摘要

项目成果

MICHAEL A. RUBIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY We enthusiastically propose to renew our CDC Prevention Epicenter, entitled “InterMountain Program in Antibiotic Resistance and microbial Threats (IMPART). Our proposal assembles an exceptional group of investigators who have an extraordinary capacity to conduct large-scale observational studies, as well as lead or co-lead interventional studies that range in scope from small pilots to multi-community randomized trials The University of Utah is the hub for our program, with Intermountain Health, a large regional integrated health system, serving as a major node. The Veterans Affairs (VA) Salt Lake City Healthcare System is another key partner for our Prevention Epicenter site, operating within a programmatic network that encompasses the entire VA health system. The resources that we bring to the CDC Prevention Epicenter Program will be broadly beneficial to its mission to improve healthcare safety and prevent healthcare-associated infection. We have accumulated the experience in translational research and expertise in multi-disciplinary methods to make significant contributions to improve the quality of antibiotic use, combat antibiotic resistance, and enhance health system response to microbial threats across the continuum of care. Moreover, we have developed a computational environment to support comprehensive epidemiological analysis of infections within the Department of Veterans Affairs (VA) Health System, as well as Intermountain Healthcare and University of Utah Health (UHealth). Our proposed research has a high level of significance for policy-making and implementation. Core Project 1 evaluates alternative implementation strategies for outpatient stewardship and advances dissemination of best practices for AS. Core Project 2 tackles a longstanding source of controversy in the healthcare epidemiology community, namely, the role of active surveillance and contact precautions (CP) in preventing healthcare-associated infection due to endemic multi-drug resistant organisms (MDRO) such as methicillin-resistant Staphylococcus aureus (MRSA). A period of partial CP deimplementation in some VA facilities, triggered in response to the emergence of COVID-19, creates the opportunity to study the impact of this natural experiment. Core Project 3 links an epidemiological analysis of transmission pathways in LTC facilities to the development and implementation of novel approaches to improve practice. Core Project 4 confronts the global health challenge of COVID-19, to enhance preparedness for future epidemics and increase understanding of how to control healthcare spread of both seasonal and novel viruses. We are committed to active engagement with other Prevention Epicenter sites on collaborative projects and to work closely with public health entities at national, state, and local levels. We also pledge to contribute to programmatic domains and pathogen-specific workgroups set up under the auspices of the Prevention Epicenter Program. For all of our activities, close alignment with the health priorities of CDC will be established, along with substantial programmatic involvement of CDC staff.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intermountain Program on Antibiotic Resistance and microbial Threats (IMPART)
  • 批准号:
    10466713
  • 项目类别:
  • 资助金额:
    $26.08万
  • 财政年份:
    2021
  • 负责人:
    MICHAEL A. RUBIN
  • 依托单位:
Antimicrobial Use and Control of Clostridium difficile transmission and infection
Antimicrobial Use and Control of Clostridium difficile transmission and infection
Improving MRSA control through simulation and surveillance
海外基金